AlphaMark Advisors’s Genmab GMAB Stock Holding History

AlphaMark Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-22	Closed	–	–	571
2020 Q1	$0	Buy	+22	New	+$490	﹤0.01%	597

Other funds holding GMAB

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AlphaMark Advisors's GMAB Position: Q2 2020 in Review

AlphaMark Advisors sold out of Genmab (GMAB) in Q2 2020, closing a stake of 22 shares.

AlphaMark Advisors first reported a position in GMAB in Q1 2020 and held it in 1 quarter. The position peaked at $0 in Q1 2020. 174 funds tracked by Wall St. Rank hold GMAB as of Q2 2020.

AlphaMark Advisors reported no remaining Genmab position as of Q2 2020 after selling out during the quarter.
AlphaMark Advisors sold 22 Genmab shares in Q2 2020.
AlphaMark Advisors first reported a position in Genmab in Q1 2020 and held it in 1 quarter.
AlphaMark Advisors's Genmab position peaked at $0 in Q1 2020.
174 funds tracked by Wall St. Rank held Genmab as of Q2 2020.

Based on AlphaMark Advisors's 13F filing for Q2 2020, filed 10 Aug 2020.